SK862004A3 - Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan - Google Patents

Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan Download PDF

Info

Publication number
SK862004A3
SK862004A3 SK86-2004A SK862004A SK862004A3 SK 862004 A3 SK862004 A3 SK 862004A3 SK 862004 A SK862004 A SK 862004A SK 862004 A3 SK862004 A3 SK 862004A3
Authority
SK
Slovakia
Prior art keywords
cetuximab
solution
liquid pharmaceutical
pharmaceutical composition
polyoxyethylene
Prior art date
Application number
SK86-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Hanns-Christian Mahler
Robert Muller
Ulrike Martini-Marr
Udo Haas
Christiane Bachmann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK862004A3 publication Critical patent/SK862004A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK86-2004A 2001-07-13 2002-06-18 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan SK862004A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10133394A DE10133394A1 (de) 2001-07-13 2001-07-13 Flüssige Formulierung enthaltend Cetuximab
PCT/EP2002/006696 WO2003007988A1 (de) 2001-07-13 2002-06-18 Flüssige formulierung enthaltend cetuximab und einen polyoxyethylensorbitanfettsäureester

Publications (1)

Publication Number Publication Date
SK862004A3 true SK862004A3 (en) 2004-07-07

Family

ID=7691220

Family Applications (1)

Application Number Title Priority Date Filing Date
SK86-2004A SK862004A3 (en) 2001-07-13 2002-06-18 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan

Country Status (18)

Country Link
US (1) US20040170632A1 (cs)
EP (1) EP1406658A1 (cs)
JP (1) JP2004536129A (cs)
KR (1) KR20040018458A (cs)
CN (1) CN1231264C (cs)
AR (1) AR039358A1 (cs)
BR (1) BR0211060A (cs)
CA (1) CA2453342A1 (cs)
CZ (1) CZ2004189A3 (cs)
DE (1) DE10133394A1 (cs)
HU (1) HUP0401046A3 (cs)
MX (1) MXPA04000340A (cs)
PE (1) PE20030433A1 (cs)
PL (1) PL364599A1 (cs)
RU (1) RU2004102395A (cs)
SK (1) SK862004A3 (cs)
WO (1) WO2003007988A1 (cs)
ZA (1) ZA200401161B (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103040732B (zh) 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
EP1713502A1 (de) * 2004-02-12 2006-10-25 MERCK PATENT GmbH Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
US20070207149A1 (en) * 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
PL1859793T3 (pl) * 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
EP1982718A4 (en) 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
JP2009535372A (ja) 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN112566652A (zh) * 2018-06-25 2021-03-26 Jcr制药股份有限公司 含有蛋白的水性液体制剂
EA202190590A1 (ru) * 2018-08-31 2021-07-16 Ампликс Фармасьютикалз, Инк. Соединения и способы лечения грибковых инфекций
WO2025113442A1 (zh) * 2023-11-29 2025-06-05 四川科伦博泰生物医药股份有限公司 抗体制剂
TW202612729A (zh) 2024-05-22 2026-04-01 美商提聖納醫療公司 涉及抗ｈｌａ－ｇ抗體及抗ｅｇｆｒ抗體以及抗ｐｄ－１抗體之組合療法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation

Also Published As

Publication number Publication date
CN1231264C (zh) 2005-12-14
PL364599A1 (en) 2004-12-13
EP1406658A1 (de) 2004-04-14
BR0211060A (pt) 2004-07-20
HUP0401046A2 (en) 2006-04-28
CN1527724A (zh) 2004-09-08
RU2004102395A (ru) 2005-05-27
MXPA04000340A (es) 2004-05-04
CA2453342A1 (en) 2003-01-30
AR039358A1 (es) 2005-02-16
KR20040018458A (ko) 2004-03-03
CZ2004189A3 (cs) 2004-05-12
HUP0401046A3 (en) 2006-11-28
ZA200401161B (en) 2004-10-22
JP2004536129A (ja) 2004-12-02
PE20030433A1 (es) 2003-05-24
US20040170632A1 (en) 2004-09-02
DE10133394A1 (de) 2003-01-30
WO2003007988A1 (de) 2003-01-30

Similar Documents

Publication Publication Date Title
US20230047111A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
JP7473603B2 (ja) 液体医薬組成物
CN100515495C (zh) 包含抗egf受体抗体的冻干制剂
JP4317010B2 (ja) ＩｇＧ抗体の安定な凍結乾燥医薬製剤
TWI322693B (en) Pharmaceutical preparation comprising an antibody against the egf receptor
US11712472B2 (en) Pharmaceutical composition comprising anti-human TSLP receptor antibody
CZ2004189A3 (cs) Název neuveden
TWI856084B (zh) 用於穩定含有蛋白質之配方之組合物及方法
JP3714951B2 (ja) Ｉｌ−６含有薬剤組成物
JP6885875B2 (ja) 液体医薬組成物
CN118076380A (zh) 免疫检查点抑制剂的药物配制物
CA3256560A1 (en) LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF COPPER HISTIDINATE
HK1065261A (en) Liquid formulation comprising cetuximab and a polyoxyethylene sorbitan fatty acid ester
HK1095534B (en) Pharmaceutical preparation containing an antibody against the egf receptor
HK40005809B (en) Liquid pharmaceutical composition
WO2025113442A1 (zh) 抗体制剂
OA17126A (en) Pharmaceutical formulations of TNF-alpha antibodies

Legal Events

Date Code Title Description
FC9A Refused patent application